This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watanabe, A.
Right arrow Articles by Nukiwa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watanabe, A.
Right arrow Articles by Nukiwa, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1767-1768, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections

Akira Watanabe,* Yutaka Tokue, Hiroshi Takahashi, Tohru Kikuchi, Takao Kobayashi, Kazunori Gomi, Shigeru Fujimura, and Toshihiro Nukiwa

Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Japan

Received 17 August 1998/Returned for modification 7 January 1999/Accepted 4 May 1999

The in vitro activity of HSR-903, an oral quinolone, against 196 recent clinical isolates of respiratory pathogens was evaluated. HSR-903 was 2 to 32 times more active than ofloxacin, ciprofloxacin, and sparfloxacin against Staphylococcus aureus, including methicillin-resistant strains, and Streptococcus pneumoniae and was at least as active as the other quinolones against gram-negative pathogens.

* Corresponding author. Mailing address: Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University, 4-1, Seiryo-cho, Aoba-ku, Sendai 980-8575, Japan. Phone and fax: 81-22-717-8540. E-mail: akiwa{at}idac.tohoku.ac.jp.

Antimicrobial Agents and Chemotherapy, July 1999, p. 1767-1768, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Higa, F., Arakaki, N., Tateyama, M., Koide, M., Shinzato, T., Kawakami, K., Saito, A. (2003). In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp.. J Antimicrob Chemother 52: 920-924 [Abstract] [Full Text]  
  • Yoshizumi, S., Takahashi, Y., Murata, M., Domon, H., Furuya, N., Ishii, Y., Matsumoto, T., Ohno, A., Tateda, K., Miyazaki, S., Yamaguchi, K. (2001). The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. J Antimicrob Chemother 48: 137-140 [Abstract] [Full Text]  
  • Tomioka, H., Sato, K., Akaki, T., Kajitani, H., Kawahara, S., Sakatani, M. (1999). Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafloxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium Complex. Antimicrob. Agents Chemother. 43: 3001-3004 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»